Yang et al. (2017) reported that evodiamine downregulated cell viability and inhibited cell cycle progression in human HCC HepG2 cells by decreasing p-Akt level and increasing the levels of apoptotic proteins Bax, cleaved-caspase-3 and cleaved-PARP (poly (ADP-ribose) polymerase) [44]. Here, CASP3 is linked to hepatocellular carcinoma.